Bekmezian Arpi, Hersh Adam L, Maselli Judith H, Cabana Michael D
Department of Pediatrics, University of California, San Francisco, CA 94143-0110, USA.
J Asthma. 2011 Feb;48(1):69-74. doi: 10.3109/02770903.2010.535884. Epub 2010 Nov 30.
To determine whether systemic corticosteroids are under-prescribed (as measured by current NIH treatment guidelines) for children in the United States seen in the emergency department (ED) for acute asthma, and to identify factors associated with prescribing systemic corticosteroids.
We used data from the 2001-2007 National Hospital Ambulatory Medical Care Survey. The study population was children ≤ 18 years old in the ED with a primary diagnosis of asthma (ICD-9-CM code 493.xx) who received bronchodilator(s). The primary outcome was receipt of a systemic corticosteroid in the ED. Independent variables included patient-level (e.g., demographics, insurance, fever, admission), physician-level (provider type, ancillary medications and tests ordered), and system-level factors (e.g., ED type, geographic location, time of day, season, year). We used multivariable logistic regression techniques to identify factors associated with systemic corticosteroid treatment.
Systemic corticosteroids were prescribed at only 63% of pediatric acute asthma visits to EDs. Over the study period, there was a trend toward increasing systemic corticosteroid use (p for trend = .05). After adjusting for potential confounders, patients were more likely to receive systemic corticosteroids when treated in pediatric EDs than in general EDs (OR = 2.45; 95% CI: 1.26-4.77).
Systemic corticosteroids are under-prescribed for children who present to EDs with acute asthma exacerbations. Pediatric EDs are more likely than general EDs to treat asthma exacerbations with systemic corticosteroids. Differences in the process of care in pediatric ED settings (compared to general EDs) may increase the likelihood of adherence to NIH treatment guidelines.
确定在美国急诊科因急性哮喘就诊的儿童中,全身用皮质类固醇的处方是否不足(根据美国国立卫生研究院当前的治疗指南衡量),并识别与开具全身用皮质类固醇相关的因素。
我们使用了2001 - 2007年全国医院门诊医疗调查的数据。研究人群为急诊科中≤18岁、以哮喘为主要诊断(国际疾病分类第九版临床修正本代码493.xx)且接受了支气管扩张剂治疗的儿童。主要结局是在急诊科接受全身用皮质类固醇治疗。自变量包括患者层面的因素(如人口统计学特征、保险情况、发热、住院情况)、医生层面的因素(提供者类型、所开具的辅助药物和检查)以及系统层面因素(如急诊科类型、地理位置、一天中的时间、季节、年份)。我们使用多变量逻辑回归技术来识别与全身用皮质类固醇治疗相关的因素。
在儿科急性哮喘患者到急诊科就诊的病例中,仅63%开具了全身用皮质类固醇。在研究期间,全身用皮质类固醇的使用有增加趋势(趋势p值 = 0.05)。在对潜在混杂因素进行调整后,与在普通急诊科接受治疗的患者相比,在儿科急诊科接受治疗的患者更有可能接受全身用皮质类固醇治疗(比值比 = 2.45;95%置信区间:1.26 - 4.77)。
对于因急性哮喘加重到急诊科就诊的儿童,全身用皮质类固醇的处方不足。与普通急诊科相比,儿科急诊科更有可能使用全身用皮质类固醇治疗哮喘加重。儿科急诊科环境中的护理过程差异(与普通急诊科相比)可能会增加遵循美国国立卫生研究院治疗指南的可能性。